8-KLeadership ChangesMaterial AgreementsExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Material Agreement (Nov 30, 2012)

Filed November 30, 2012For Securities:ABT

Summary

Abbott Laboratories (ABT) filed an 8-K on November 30, 2012, detailing significant corporate actions related to the planned separation of its research-based pharmaceuticals business into a new entity, AbbVie Inc. The filing formally documents the entry into a Separation and Distribution Agreement between Abbott and AbbVie, outlining the terms for distributing 100% of AbbVie's common stock to Abbott shareholders and governing their ongoing relationship post-separation. This event is a critical step towards the spin-off, allowing Abbott to focus on its diversified medical products portfolio while AbbVie will operate as an independent biopharmaceutical company. The report also addresses changes to change-in-control agreements for certain Abbott executive officers, effective December 1, 2012. These revised agreements, notably for Thomas C. Freyman, Richard A. Gonzalez, and Laura J. Schumacher, eliminate automatic renewal features and "golden parachute" tax gross-up payments, aligning them with a more tax-efficient structure. Amendments to certain grantor trust-funded compensation plans also reflect a shift towards pre-tax benefit expression and the removal of tax gross-ups for departing employees after January 1, 2013. These changes indicate a strategic realignment and a focus on more streamlined executive compensation and employee benefit structures.

Key Highlights

  • 1Abbott Laboratories finalized a Separation and Distribution Agreement with AbbVie Inc., paving the way for the planned spin-off of its research-based pharmaceutical business.
  • 2The agreement details the distribution of 100% of AbbVie's common stock to Abbott shareholders, marking a significant step in the separation process.
  • 3New Change in Control Agreements were entered into with certain executive officers, effective December 1, 2012, replacing prior agreements.
  • 4Key modifications to the executive Change in Control Agreements include the removal of automatic renewal features and "golden parachute" tax gross-up payments.
  • 5Severance payments under the new agreements are structured to prevent excise tax application, potentially resulting in a better after-tax position for executives.
  • 6Amendments to certain grantor trust-funded compensation plans will express benefits on a pre-tax basis and eliminate all tax gross-up features for employees leaving after January 1, 2013.

Frequently Asked Questions

The primary purpose of this 8-K filing is to report the formal entry into a Separation and Distribution Agreement between Abbott Laboratories and its subsidiary AbbVie Inc., which is essential for the planned separation and spin-off of Abbott's research-based pharmaceutical business.

The revised Change in Control Agreements for certain executives remove automatic renewal and eliminate tax gross-up payments for 'golden parachute' excise taxes. While severance benefits remain for termination within two years post-change of control, the structure is designed to be more tax-efficient, potentially benefiting executives by avoiding excise taxes if it results in a better after-tax outcome.

Amendments to certain grantor trust-funded compensation plans will change how benefits are expressed (on a pre-tax basis) and eliminate all tax gross-up features for participants who retire or leave employment on or after January 1, 2013. This means employees will receive their benefits without Abbott covering the taxes associated with them.

AbbVie Inc. is a wholly owned subsidiary of Abbott Laboratories that houses Abbott's research-based pharmaceutical business. The Separation and Distribution Agreement outlines the terms for spinning off AbbVie as an independent company, with its common stock to be distributed to Abbott's shareholders.